Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

INTS Intesity Therapeutics Inc

1,8668

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 14:06:53

Verzögert um 15 Minuten

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Intesity Therapeutics (NASDAQ:INTS)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Intesity Therapeutics Charts.

Intesity Therapeutics (NASDAQ:INTS)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Intesity Therapeutics Charts.

News Intesity Therapeutics Inc

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Montag 30 Dezember 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Freitag 20 Dezember 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Freitag 13 Dezember 2024 (4 Wochen vor) • Edgar (US Regulatory)

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer
Donnerstag 12 Dezember 2024 (4 Wochen vor) • PR Newswire (US)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Freitag 22 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Freitag 22 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Donnerstag 21 November 2024 (2 Monate vor) • PR Newswire (US)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Mittwoch 20 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Montag 18 November 2024 (2 Monate vor) • PR Newswire (US)

Form 8-K - Current report
Mittwoch 13 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Mittwoch 13 November 2024 (2 Monate vor) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 13 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Intesity Therapeutics Inc News-Artikel

Koninklijke Philips NV

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen